(Q34648375)

3 August 2017

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks (English)

1 reference

3 August 2017

0 references

1 reference

H-C Diener

1

1 reference

3 August 2017

RPR100893 Study Group

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

3 August 2017

1 reference

3 August 2017

23

1 reference

3 August 2017

3

1 reference

3 August 2017

183-185

1 reference

Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580.

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

Substance P receptor antagonists in the therapy of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

Lanepitant, an NK-1 antagonist, in migraine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-2982.2003.00496.X

10.1046/J.1468-2982.2003.00496.X

21 January 2018

Identifiers

DOI

1 reference

release_dc5pkz2ki5gylk4oghmb7ey3i4

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dc5pkz2ki5gylk4oghmb7ey3i4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference